No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
SAGE240517P20000
- 8.00
- 0.000.00%
15min DelayClose Apr 17 12:25 ET
0.00High0.00Low
8.00Open8.00Pre Close0 Volume87 Open Interest20.00Strike Price0.00Turnover0.00%IV0.48%PremiumMay 17, 2024Expiry Date7.61Intrinsic Value100Multiplier9DDays to Expiry0.39Time Value100Contract SizeAmericanOptions Type--Delta--Gamma1.64Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Major Depressive Disorder Pipeline Insights Report, 2024 Featuring 75+ Companies and Pipeline Drugs, Including SAGE-217 (Sage Therapeutics) and REL-1017 (Relmada Therapeutics)
Sage Therapeutics to Participate in Upcoming May Investor Conferences
Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in the following upcoming investor
Sage Therapeutics Is Maintained at Overweight by JP Morgan
Sage Therapeutics Is Maintained at Overweight by JP Morgan
JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $28
JP Morgan analyst Anupam Rama maintains Sage Therapeutics (NASDAQ:SAGE) with a Overweight and lowers the price target from $29 to $28.
Express News | Sage Therapeutics Inc : JP Morgan Cuts Target Price to $28 From $29
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript
Comments
Pre-Market Stock Movers
Gapping up
$Salesforce(CRM.US$ jumped 6.2% following its earnings beat after the bell Wednesday. Adjusted earnings per share came in at $2.12 for the second quarter, versus the consensus estimate of $1.90, per Refinitiv. Revenue was $8.60 billion, topping the $8.53 expected. Goldman Sachs subsequently hiked its price target by $15 to $340 a share, suggestions 58% upside.
$UBS Group(UBS.US$ popp...
Gapping up
$Salesforce(CRM.US$ jumped 6.2% following its earnings beat after the bell Wednesday. Adjusted earnings per share came in at $2.12 for the second quarter, versus the consensus estimate of $1.90, per Refinitiv. Revenue was $8.60 billion, topping the $8.53 expected. Goldman Sachs subsequently hiked its price target by $15 to $340 a share, suggestions 58% upside.
$UBS Group(UBS.US$ popp...
24
1
$Apellis Pharmaceuticals(APLS.US$ $Alteryx(AYX.US$ $Barfresh Food(BRFH.US$ $Celanese Corp(CE.US$ $Chegg(CHGG.US$ $Chewy(CHWY.US$ $Extra Space Storage Inc(EXR.US$ $Five9(FIVN.US$ $International Flavors & Fragrances(IFF.US$ $Lucid Group(LCID.US$ $Paramount Global-B(PARA.US$ $Sage Therapeutics(SAGE.US$ $ShockWave Medical(SWAV.US$ $Teradata Corp(TDC.US$ $VistaGen Therapeutics(VTGN.US$ $Wynn Resorts(WYNN.US$
follow for daily watchlist 🚀
follow for daily watchlist 🚀
3
$Sage Therapeutics(SAGE.US$
Great entry point. As long as it is approved and on the market, it will be open for off-label use for MDD if someone really wants it.
Great entry point. As long as it is approved and on the market, it will be open for off-label use for MDD if someone really wants it.
1
$Sage Therapeutics(SAGE.US$ the medicine got approval as a quick fix for PPD 产后抑郁症 after delivery. It can make some big money for that. Sorry but women have many troubles after delivery. Well done.
However MDD 一般抑郁症 is not approved. Although they are not serious enough for MDD. MDD means huge money. And people with MDD typically take pills for years. Guess what, wall street and elites, they know mental health better than you
Now no huge money but just big mon...
However MDD 一般抑郁症 is not approved. Although they are not serious enough for MDD. MDD means huge money. And people with MDD typically take pills for years. Guess what, wall street and elites, they know mental health better than you
Now no huge money but just big mon...
2
Read more
taijahmed75OP : Adding the link here: These Five Biotech Stocks Are Developing Potentially Groundbreaking Mental Health Treatments